Slide NEUROLOGICAL IMPAIRMENT LABORATORY Carmina Montoliu Felix





The Joint Unit on Neurological Impairment CIPF-INCLIVA performs basic and translational research on cognitive, motor, sleep and circadian rhythms alterations in different pathological situations, including: minimal and clinical hepatic encephalopathy (HE), hyperammonemia and developmental exposure to food and environmental contaminants. We also apply our wide range of methodologies to other pathological situations. The aims are:

In animal models:

  1. Unveil the molecular mechanisms leading to neurological impairment
  2. Identify new therapeutic targets for its treatment
  3. Design and assess new therapeutic procedures to reverse neurological impairment In patients
  4. Study the mechanisms, diagnosis and treatment of neurological impairment
  5. Identify early diagnostic procedures for neurological impairment
  6. Bring to the clinic the diagnostic procedures identified

Presentation

Get to know us better

Research Staff

The people who make it all possible

Eloisa Jantus Lewintre

Carlos Camps Herrero

Silvia Calabuig Fariñas

Macarena Ferrero Gimeno

Jose Vicente Bagan Sebastian

Ricardo Guijarro Jorge

Miguel Martorell 

Ana Blasco Cordellat

Alfonso Berrocal Jaime

Vega Iranzo González-cruz

Eva Escorihuela Alares

Andrea Moreno Manuel

Susana Torres Martinez

Publications

Our scientific contributions

dPCR application in liquid biopsies: divide and conquer
A. MORENO-MANUEL, S. CALABUIG-FARINAS, A. OBRADOR-HEVIA, A. BLASCO, A. FERNANDEZ-DIAZ, R. SIRERA, C. CAMPS and E. JANTUS-LEWINTRE
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021 Jan,  Vol. 21,  pag. 3-15

CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
A. MORENO-MANUEL, E. JANTUS-LEWINTRE, I. SIMOES, F. ARANDA, S. CALABUIG-FARINAS, E. CARRERAS, S. ZUNIGA, Y. SAENGER, R. ROSELL, C. CAMPS, F. LOZANO and R. SIRERA
Translational Lung Cancer Research, 2020 Aug,  Vol. 9,  pag. 1074

Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice.
Camps C, Badia X, García-Campelo R, García-Foncillas J, López R, Massuti B, Provencio M, Salazar R, Virizuela J and Guillem V
Jco Oncology Practice, 2020 Mar,  Vol. 16,  pag. e298-e305

Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma.
Chaib I, Cai X, Llige D, Santarpia M, Jantus-Lewintre E, Filipska M, Pedraz C, Cui J, Yang J, Miao J, Sun R, Bracht JWP, Ito M, Codony-Servat J, Karachaliou N, Aguilar A, Rosell R and Cao P
Annals of Translational Medicine, 2019 Nov,  Vol. 7,  pag. 651-651

Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer
Herreros-Pomares A, de-Maya-Girones JD, Calabuig-Fariñas S, Lucas R, Martínez A, Pardo-Sánchez JM, Alonso S, Blasco A, Guijarro R, Martorell M, Escorihuela E, Chiara MD, Duréndez E, Gandía C, Forteza J, Sirera R, Jantus-Lewintre E, Farràs R and Camps C
Cell Death & Disease, 2019 Sep,  Vol. 10,  pag. 660-660

FUNDING

Thank you for supporting us